Autolus Therapeutics plc (AUTL) is a Biotechnology company in the Healthcare sector, currently trading at $1.50. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is AUTL = $9 (+491.3% upside).
Valuation: AUTL trades at a trailing Price-to-Earnings (P/E) of -1.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.06.
Financials: revenue is $76M, +356.7%/yr average growth. Net income is $288M (loss), growing at -25.4%/yr. Net profit margin is -380.5% (negative). Gross margin is -27.8% (+2087.6 pp trend).
Balance sheet: total debt is $352M against $178M equity (Debt-to-Equity (D/E) ratio 1.97, leveraged). Current ratio is 5.94 (strong liquidity). Debt-to-assets is 59.7%. Total assets: $589M.
Analyst outlook: 11 / 14 analysts rate AUTL as buy (79%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 15/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
